Seladelpar sodium salt (MBX-8025) is an orally active and specific PPARδ agonist with an EC50 of 2 nM, demonstrating over 750-fold and 2500-fold selectivity compared to the PPARα and PPARγ receptors, respectively.

PPARδ:2 nM （EC50）

MBX-8025 is an orally active, potent (EC50 = 2 nM) PPARδ agonist, exhibiting 750-fold and 2500-fold higher specificity compared to PPARα and PPARγ receptors, respectively, and is being developed as a lipid-altering agent [2] [3].

In a study involving Wt mice on an atherogenic diet, Seladelpar sodium salt administration led to a significant reduction of approximately 18% in body weight (P<0.05), whereas its impact on foz/foz mice under the same diet was minimal. Additionally, this compound significantly lowered serum alanine aminotransferase (ALT) levels in foz/foz mice (P<0.05) and exhibited a similar, though not significant, effect in Wt mice. Seladelpar sodium salt was effective in normalizing serum cholesterol levels and reducing triglycerides across both mouse genotypes (P<0.05). It also eliminated hepatocyte ballooning (P<0.05) and halved the nonalcoholic fatty liver disease (NAFLD) activity score by approximately 50%. Moreover, the compound notably diminished sirius red-positive areas in foz/foz mice (P<0.05) [4].